TLOG

Tetralogic Pharmaceuticals Corporation

An oncology-focused biopharmaceutical company that designed small-molecule drugs meant to coax cancer cells into dying on their own. Its lead drug, birinapant, mimics a natural protein to strip cancer cells of their ability to escape cell death, and the firm also worked on drugs to block harmful necrosis. The name 'TetraLogic' comes from its drug design being based on four amino acids — a tetrapeptide — copied from that natural protein. Founded in 2001 and based in Malvern, Pennsylvania.

No Schedule 13D or 13G filings recorded.